Whole Body Health Sale

Life Extension Magazine

Life Extension Magazine December 2012
Report  

The PSA Controversy
Part II

By Stephen B. Strum, MD, FACP
The PSA Controversy 2  

Part II of this article on PSA Screening shares detailed information on a young man who represents many thousands of men who have a father or brother with prostate cancer and who have undergone PSA screening despite the United States Preventive Services Task Force's recommendations not to use the PSA for screening—even in men with high-risk factors. Here Dr. Strum will point out how PSA screening and subsequent PSA testing can:

  1. Facilitate an early diagnosis of prostate cancer,
  2. Lead to a more informed assessment of a man's health status,
  3. Use this information to correct many subclinical findings of ill health,
  4. Ensure stability of the prostate cancer process, and
  5. Allow, when indicated, a detour from the conventional response to a diagnosis of prostate cancer which typically mandates an invasive treatment, be it radical prostatectomy, radiation therapy in any form, cryosurgery or high intensity focused ultrasound.

This real-world case history shows how PSA screening can be used as a tool to diagnose and treat prostate cancer without resorting to the inappropriate use of side effect laden therapies.

This article provides highly technical details of a successful treatment involving a man named Andy who contracted prostate cancer at a young age. What you'll learn is the kind of personal attention the International Strategic Cancer Alliance provides to its clients. If you have prostate cancer and find the material in this article overly technical, you may consider enrolling as a client of the International Strategic Cancer Alliance by calling the phone number that appears at the end of this article.

Andy's first PSA was obtained in 1993 when he was 43 years of age. He was told that the result was normal because it was less than 4.0 ng/mL. Three years later it was slightly higher at 1.4 ng/mL, and approximately four more years later it had risen to 1.8 ng/mL. Andy's PSA's prior to his diagnosis of PC show a serial rise—not a saw-tooth or up and down pattern that is characteristic of inflammation of the prostate (prostatitis). Andy had been using the same laboratory for his PSA testing and almost all of his blood sampling was done in the morning. Andy was not aware of the effect of ejaculation on raising PSA test results1-4 since my involvement in his care did not occur until September 2007.

In Table 1 the PSA values of the son (Andy) of one of my patients (Dick) with established Prostate Cancer are shown.

Date PSA Date PSA
3/8/93 1.2 12/8/08 5.1
7/19/96 1.4 1/6/09 4.3
4/14/00 1.8 2/17/09 3.9
7/30/01 2.0 6/12/09 4.0
3/10/04 2.4 10/26/09 3.6
9/19/05 2.5 4/9/10 3.8
10/17/06 2.9 7/8/10 3.7
9/5/07 2.92 10/5/10 3.6
9/27/07 Diagnosed with prostate cancer 2/8/11 3.8

TABLE 1: PSA Values for Andy. Recommendations for PSA testing were begun immediately after the patient's father was diagnosed with PC. In patients with a family history of PC, breast cancer or colorectal cancer, initial testing should begin at age 35 to establish a baseline.

An additional aspect of PSA testing that is important to communicate in the context of Andy's clinical course is how the PSA value relates to tumor (cancer) volume. All cells, including cancer cells make hundreds of products that include proteins, enzymes, etc. These are functional products and have relevance to the survivability, growth, and spread of cancer cells.

PSA functions to break down the extra-cellular tissue to allow spread of disease. Therefore, PSA is a detrimental enzyme when elevated because it can facilitate prostate cancer cell invasion.5 Each prostate cancer cell produces and secretes into the blood a certain amount of the biomarker—PSA, and this amount or leak of PSA into the blood relates to the aggressiveness of the individual patient's cancer cell population.

What is seen with Andy prior to his established diagnosis of PC on 9/27/07 is a slow but inexorable rise in PSA. Every new value is greater than the previous value. These values have been entered into a software program called PC Tools (www.lef.org/downloads/PCTII.zip) shown in Table 2. The change in PSA per year or PSA velocity (PSAV) is shown in the right column for each couplet of dates. The PSAVs look consistent with BPH (benign prostatic hypertrophy) since they are in the range of 0.1 ng/mL/yr. But then, between 2005 and 2006 the PSAV increases to a threshold of moderate concern or ≥ 0.3 ng/mL/yr.

An analysis of the PSA slope or trend (see Figure 1) from 1993 to 2007 shows increasing values of the natural log PSA value and a graph that again poses concern for prostate cancer (PC). If this were BPH there should be a more gradual slope. The software program using Excel is provided to you at www.lef.org/downloads/PCTII.zip at no charge.

Downloading: When the browser prompts how to handle the file, choose Open. From the list of files, double-click the one named 'Project1'.

Andy shared his concerns with his general practitioner and with the urologist that he was referred to. A DRE (digital rectal exam) indicated a T1c clinical stage (no pathological findings).6 Transrectal ultrasound guided biopsies were done and seven cores from both the right and left lobes were obtained.

Prostate cancer was found to involve three of seven cores of both the right and left lobes for a core percentage of 42.8%. The PC tissue involvement was 11mm of 161mm or 6.9%.7 The Gleason score evaluation by Helmut Bonkhoff, MD, an expert in PC pathology, was (3,3) or six.

A clear diagnosis of prostate cancer (PC) had been established. This was a young man with approximately 40 more years of estimated life expectancy. PC was found in almost half of the core biopsies. What should he do?

Andy's status relating to many of the co-related health issues associated with PC was examined. These associations include, but are not limited, to bone loss, elevated LDL, abnormal fatty acid indicators of excessive inflammation, low vitamin D metabolite levels, and glucose intolerance. For example, because of the significant correlation of osteoporosis and osteopenia with newly diagnosed men with PC,8 a quantitative computerized tomography (QCT) bone density (not to be confused with a bone scan, or with a DEXA bone density) was obtained. This revealed a bone mineral density (BMD) of 121 grams/cc for a T score of –2.03 involving the L1 to L3 lumbar vertebrae; this indicated significant osteopenia. The BMD at the left hip femoral neck revealed a T score of –1.58 consistent with osteopenia of a milder degree.

Table 2  

Emphasizing the association of PC, and all cancers, with other health conditions, an understanding of the biology of cancer makes such associations easily understandable. Cancer cells require energy or fuel to enable proliferation, growth, invasion, and metastasis. These fuels include glucose, omega-6 fatty acids, low density lipoprotein (LDL), and glutamine.9-11 Andy was advised to obtain an NMR LipoProfile via LipoScience (http://bit.ly/veAZnq), which unlike the standard "cholesterol panel" or "lipid panel" quantitates the various lipid particles. The results of this study showed an LDL of 122 mg/dL (optimal <100 mg/dL), and a total particle LDL value of 1,115 nmol/L (optimal <1,000 nmol/L) and a small particle LDL of 702 nmol/L (optimal <600 nmol/L). A metabolite of vitamin D-3 named (25-OH)-D3 has been shown to be an anti-proliferative vitamin and some studies show (25-OH)-D3 supplementation has an anti-PC effect.12 Andy's 25-hydroxyvitamin D blood level was very low at 23.5 ng/mL with a desired threshold level of at least 60 ng/mL, and an optimal level of 80 ng/mL.13 Andy was placed on vitamin D-3 dose of 5,000 IU per day, with advised to recheck 25-hydroxyvitamin D level after 1-2 months.

Andy's homocysteine (Hcy) level was 4.5 µmol/L, with optimal values being less than 7 µmol/L.14,15 Hcy is an inflammatory substance and has been shown to be elevated proportionally to the amount (volume) of prostate cancer.16,17 A serum testosterone level was 509 ng/dL, which was considered acceptable, but not at the optimal level of at least 550 ng/dL.18 The serum prolactin of 9.4 ng/mL was not optimal and given that prolactin stimulates angiogenesis19-23 and also sensitizes the androgen receptor to the effects of male hormones testosterone and dihydrotestosterone (DHT),24-26 treatment with cabergoline (Dostinex®) to lower prolactin was recommended. A serum PAP (prostatic acid phosphatase) was normal at 1.5 ng/mL indicating a lower risk for PC spreading beyond the capsule of the prostate.27-31 All of the above investigations fine tune the care of any man with PC, and detects abnormalities that if uncorrected could lead to serious medical conditions that are then attributed to the treatment of PC. This is part of the Paul Harvey "and now for the rest of the story." A few more examples of investigating the whole patient to understand his unique biology are given below. Indeed, MD should stand for medical detective.

Figure 1  

A Comprehensive Fatty Acid (CFA) profile panel was obtained from the Mayo Medical Labs to evaluate various omega-3 and omega-6 fatty acids. Arachidonic acid (AA) and linoleic acid are two omega-6 fatty acids which are pro-inflammatory and act as growth stimulants for PC. The key omega-3 fatty acids such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) act to balance out the negative effects of the omega-6 fatty acids. The ratio of AA to EPA (AA/EPA) for Andy was optimal at 1.2. His omega-6 to omega-3 ratio was close to optimal at 2.44.32 But we learned that Andy had already begun supplementing his diet with fish oil containing 1,400 mg of EPA and 1,000 mg of DHA per day prior to any baseline testing.

Further analysis of the PC tissue obtained at biopsy was obtained using the services of Dr. Helmut Bonkhoff, an international expert in PC pathology. He performed IHC (immunohistochemistry) analyses on the PC tissue to determine if Andy's PC relied on specific enzyme pathways (gene products) to enhance oncogenic signaling crucial to cancer growth and spread. Abnormal PC tissue expressions of cyclooxygenase-2 (COX-2), fatty acid synthase (FAS), heat shock protein (HSP) and vascular endothelial growth factor (VEGF) were found. Based on peer-reviewed medical publications about dietary, supplement and drug therapies to reduce (down-regulate) the effects of these gene products, recommendations were made to Andy (see Table 3).

Table 3  
 

With this more complete evaluation of Andy's status, "refined imaging" was next advised to obtain a more comprehensive sense of the PC volume and to establish Andy's baseline profile (see http://bit.ly/LYerzy).67 An endorectal MRI and MR spectroscopy (MRS) was done at UCSF. It showed MRI abnormalities in the left apex and left base and in the central gland. MRS was abnormal in the central gland and left base. No extracapsular extension (ECE) nor seminal vesicle or regional lymph node involvement were seen. A repeat 25-hydroxyvitamin D blood test after one month of 5,000 IU of vitamin D-3 showed a doubling to 52 ng/mL. A further dose increase to 7,000 IU per day was recommended.

Andy adjusted his supplements in response to the findings in Table 3 by adding EGCG at 472 mg/day, silibinin at 85 mg/day, ginger at 10 mg/day, rosemary extract at 800 mcg/day and also increased his total EPA + DHA dose to 3,600 mg/day. He also began a natural COX-2 inhibitor product called Zyflamend® containing rosemary, turmeric, ginger, holy basil, green tea, and other agents.68-71 In May of 2008 the (25-OH)-D3 level had risen to 67.9 ng/mL. In October of 2008, Andy began Dostinex® at 2.5 mg three times a week to lower serum prolactin. He also began a resistance exercise program to improve his bone density. In December 2008 his fasting morning prolactin level had dropped to 1.1 ng/mL and he was told to reduce the Dostinex® dose to only twice a week. In early 2009, a repeat MRI at UCSF showed improvement with only a slight area of T-2 abnormality in the left aspect of the central gland remaining. No other pathology was apparent.

Since 2009, Andy has had dose adjustments of various supplements and medications based on periodically assessing BEPs (Biological End Points). BEPs are the test results that are objective data relating to diet, lifestyle or medication interventions. BEPs are identical to the LEDs on the dashboard of your car—they are status indicators. Andy has had additional BEPs that include a normal HbA1c of 5.6% to assess his handling of carbohydrates and a Cystatin C of 0.62 mg/dL which assesses renal function and inflammation.

In July 2010, an additional MRI and MRS was done at UCSF and showed no abnormal findings. However, a repeat QCT bone density showed the BMD to have decreased to 106.7 gm/cc at the lumbar spine with an associated T score of -2.6 indicating osteoporosis. Bone resorption markers (additional BEPs) that included urine testing for DpD (deoxypyridinoline) was 2.7 nmol Dpd/mmol creatinine, a normal result. A serum b-CTX (C-Terminal Telopeptide, b-Crosslaps) was slightly elevated at 375 pg/mL (normal 87-345 pg/mL). However, a repeat CTx to confirm the abnormal finding was normal at 266 pg/mL in March 2011. A follow-up NMR LipoProfile indicated small particle LDL to be <90 nmol/L and total LDL particles to be 646 nmol/L, both entirely normal.

Andy's PSA levels since his diagnosis of PC in September 2007 are shown below (Table 4). These findings show no serial increase in PSA and coupled with normal imaging studies indicate no progression of PC, and perhaps regression. Repeat prostate biopsies are being considered.

Andy's PSA Readings  

Andy is now 62 years of age. He was not pushed into any form of invasive treatment for his PC but instead he was given the various options that included RP (radical prostatectomy), RT (radiation therapy) using IMRT (intensity modulating radiation therapy), cryosurgery and HIFU (high intensity focused ultrasound). Andy has become an empowered patient that understands the value of obtaining baseline studies, follow-up BEPs, and determining strategy based on his personal status. The diagnosis of PC and the realization of the co-relationships with other areas of his health has resulted in major improvements in Andy's health (see Figure 2 on the next page).

But Andy clearly understands that he still needs to focus on issues where abnormal findings have not been resolved. In this use of PSA screening for a man with a family history of PC, all of the principles discussed in the beginning sections of this article were employed. For Andy, he has not needed an invasive treatment to control his PC. The use of the PSA facilitated an early diagnosis of PC when tumor volume was low and the PC remained confined to the prostate. Understanding the patient's context, employing various medical artists to enhance an understanding of his status, educating the patient as to foundational concepts involved in optimizing health has evolved Andy's health status compared to his state of ignorance prior to his diagnosis of PC.

PSA screening for this man has been a blessing. Not only was the message understood, but the messengers used worked together with Andy as a cohesive medical team in the spirit of collaboration and collegiality. Whether or not this can be done with the vast majority of other men who have PC are determined by the knowledge of physicians and other health care practitioners involved in the diagnosis and management of the most common malignancy affecting mankind.

Figure 2  
 

Summary

If Andy had followed the recommendations of the United States Preventative Services Task Force to not screen for PSA, he may have already undergone debilitating conventional therapies (surgery, radiation, hormone ablation, and/or chemotherapy) without the cancer being eradicated. Unlike many other cancers, certain PC patients may exert a tremendous amount of control over their disease with the appropriate use of non-toxic treatments.

This type of aggressive, yet non-toxic treatment is available to clients of the International Strategic Cancer Alliance. This article provides highly technical details of a treatment program not only for Andy's prostate cancer, but also one that corrected risk factors for vascular disease, osteoporosis, and malignancies that may have developed at other sites in Andy's body. This kind of personal attention is what the International Strategic Cancer Alliance provides to its clients. If you have prostate cancer and want to avail yourself to the comprehensive diagnostics and treatments described in this article, you may consider enrolling as a client of the International Strategic Cancer Alliance by calling 1-888-868-2981.

If you have any questions on the scientific content of this article, please call a Life Extension® Health Advisor at 1-866-864-3027.

References

1. Herschman JD, Smith DS, Catalona WJ. Effect of ejaculation on serum total and free prostate-specific antigen concentrations. Urology. Aug 1997;50(2):239-43.

2. Tchetgen MB, Oesterling JE. The effect of prostatitis, urinary retention, ejaculation, and ambulation on the serum prostate-specific antigen concentration. Urol Clin North Am. May 1997;24(2):283-91.

3. Tchetgen MB, Song JT, Strawderman M, Jacobsen SJ, Oesterling JE. Ejaculation increases the serum prostate-specific antigen concentration. Urology. Apr 1996;47(4):511-16.

4. Yavascaoglu I, Savci V, Oktay B, Simsek U, Ozyurt M. The effects of ejaculation on serum prostate-specific antigen (PSA). Int Urol Nephrol. 1998;30(1):53-8.

5. Webber MM, Waghray A, Bello D. Prostate-specific antigen, a serine protease, facilitates human prostate cancer cell invasion. Clin Cancer Res. 1995 Oct;1(10):1089-94.

6. Strum SB, Pogliano DL. A Primer on Prostate Cancer, The Empowered Patient's Guide. 2nd ed. Hollywood, Florida: Life Extension Media; 2002.

7. Freedland SJ, Terris MK, Csathy GS, et al. Preoperative model for predicting prostate specific antigen recurrence after radical prostatectomy using percent of biopsy tissue with cancer, biopsy Gleason grade and serum prostate specific antigen. J Urol. Jun 2004;171(6 Pt 1):2215-20.

8. Smith MR, McGovern FJ, Fallon MA, Schoenfeld D, Kantoff PW, Finkelstein JS. Low bone mineral density in hormone-naive men with prostate carcinoma. Cancer. Jun 15 2001;91(12):2238-45.

9. Hughes-Fulford M, Li CF, Boonyaratanakornkit J, Sayyah S. Arachidonic acid activates phosphatidylinositol 3-kinase signaling and induces gene expression in prostate cancer. Cancer Res. 2006 Feb 1;66(3):1427-33.

10. Gao P, Tchernyshyov I, Chang TC, et al. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature. 2009 Apr 9;458(7239):762-5.

11. Sekine Y, Koike H, Nakano T, Nakajima K, Takahashi S, Suzuki K. Remnant lipoproteins induced proliferation of human prostate cancer cell, PC-3 but not LNCaP, via low density lipoprotein receptor. Cancer Epidemiol. 2009 Jul;33(1):16-23.

12. Marshall DT, Savage SJ, Garrett-Mayer E, et al. Vitamin D3 supplementation at 4,000 international units per day for one year results in a decrease of positive cores at repeat biopsy in subjects with low-risk prostate cancer under active surveillance. J Clin Endocrinol Metab. 2012 Jul;97(7):2315-24.

13. Heaney RP. Assessing vitamin D status. Curr Opin Clin Nutr Metab Care. 2011 Sep;14(5):440-4.

14. Iso H, Moriyama Y, Sato S, et al. Serum total homocysteine concentrations and risk of stroke and its subtypes in Japanese. Circulation. Jun 8 2004;109(22):2766-72.

15. Spence JD. Patients with atherosclerotic vascular disease: how low should plasma homocyst(e)ine levels go? Am J Cardiovasc Drugs. 2001;1(2):85-9.

16. Wu LL, Wu JT. Hyperhomocysteinemia is a risk factor for cancer and a new potential tumor marker. Clin Chim Acta. 2002 Aug;322(1-2):21-8.

17. Sun CF, Haven TR, Wu TL, Tsao KC, Wu JT. Serum total homocysteine increases with the rapid proliferation rate of tumor cells and decline upon cell death: a potential new tumor marker. Clin Chim Acta. 2002 Jul;321(1-2):55-62.

18. Ohlsson C, Barrett-Connor E, Bhasin S, et al. High serum testosterone is associated with reduced risk of cardiovascular events in elderly men. The MrOS (Osteoporotic Fractures in Men) study in Sweden. J Am Coll Cardiol. 2011 Oct 11;58(16):1674-81.

19. Reuwer AQ, Nowak-Sliwinska P, Mans LA, et al. Functional consequences of prolactin signalling in endothelial cells: a potential link with angiogenesis in pathophysiology? J Cell Mol Med. 2012 Sep;16(9):2035-48.

20. Corbacho AM, Martínez De La Escalera G, Clapp C. Roles of prolactin and related members of the prolactin/growth hormone/placental lactogen family in angiogenesis. J Endocrinol. 2002 May;173(2):219-38.

21. Clapp C, Thebault S, Jeziorski MC, Martínez De La Escalera G. Peptide hormone regulation of angiogenesis. Physiol Rev. 2009 Oct;89(4):1177-215.

22. Struman I, Bentzien F, Lee H, et al. Opposing actions of intact and N-terminal fragments of the human prolactin/growth hormone family members on angiogenesis: an efficient mechanism for the regulation of angiogenesis. Proc Natl Acad Sci U S A. 1999 Feb 16;96(4):1246-51.

23. Ueda E, Ozerdem U, Chen YH, et al. A molecular mimic demonstrates that phosphorylated human prolactin is a potent anti-angiogenic hormone. Endocr Relat Cancer. Mar 2006;13(1):95-111.

24. Ahonen TJ, Harkonen PL, Laine J, Rui H, Martikainen PM, Nevalainen MT. Prolactin is a survival factor for androgen-deprived rat dorsal and lateral prostate epithelium in organ culture. Endocrinology. Nov 1999;140(11):5412-21.

25. Dagvadorj A, Collins S, Jomain JB, et al. Autocrine prolactin promotes prostate cancer cell growth via Janus kinase-2-signal transducer and activator of transcription-5a/b signaling pathway. Endocrinology. Jul 2007;148(7):3089-101.

26. Li H, Zhang Y, Glass A, et al. Activation of signal transducer and activator of transcription-5 in prostate cancer predicts early recurrence. Clin Cancer Res. 2005 Aug 15;11(16):5863-8.

27. Dattoli M, Wallner K, True L, Cash J, Sorace R. Long-term outcomes after treatment with external beam radiation therapy and palladium 103 for patients with higher risk prostate carcinoma: influence of prostatic acid phosphatase. Cancer. Feb 15 2003;97(4):979-83.

28. Dattoli M, Wallner K, True L, et al. Prognostic role of serum prostatic acid phosphatase for 103Pd-based radiation for prostatic carcinoma. Int J Radiat Oncol Biol Phys. Nov 1 1999;45(4):853-6.

29. Fang LC, Dattoli M, Taira A, True L, Sorace R, Wallner K. Prostatic acid phosphatase adversely affects cause-specific survival in patients with intermediate to high-risk prostate cancer treated with brachytherapy. Urology. Jan 2008;71(1):146-50.

30. Han M, Piantadosi S, Zahurak ML, et al. Serum acid phosphatase level and biochemical recurrence following radical prostatectomy for men with clinically localized prostate cancer. Urology. Apr 2001;57(4):707-11.

31. Moul JW, Connelly RR, Perahia B, McLeod DG. The contemporary value of pretreatment prostatic acid phosphatase to predict pathological stage and recurrence in radical prostatectomy cases. J Urol. Mar 1998;159(3):935-40.

32. Holub BJ. Clinical nutrition: 4. Omega-3 fatty acids in cardiovascular care. CMAJ. 2002 Mar 5;166(5):608-15.

33. Adhami VM, Malik A, Zaman N, et al. Combined inhibitory effects of green tea polyphenols and selective cyclooxygenase-2 inhibitors on the growth of human prostate cancer cells both in vitro and in vivo. Clin Cancer Res. 2007 Mar 1;13(5):1611-9.

34. Hussain T, Gupta S, Adhami VM, Mukhtar H. Green tea constituent epigallocatechin-3-gallate selectively inhibits COX-2 without affecting COX-1 expression in human prostate carcinoma cells. Int J Cancer. 2005 Feb 10;113(4):660-9.

35. Anto RJ, Mukhopadhyay A, Denning K, Aggarwal BB. Curcumin (diferuloylmethane) induces apoptosis through activation of caspase-8, BID cleavage and cytochrome c release: its suppression by ectopic expression of Bcl-2 and Bcl-xl. Carcinogenesis. Jan 2002;23(1):143-50.

36. Dhillon N, Aggarwal BB, Newman RA, et al. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res. 2008 Jul 15;14(14):4491-9.

37. Hong J, Bose M, Ju J, et al. Modulation of arachidonic acid metabolism by curcumin and related beta-diketone derivatives: effects on cytosolic phospholipase A(2), cyclooxygenases and 5-lipoxygenase. Carcinogenesis. Sep 2004;25(9):1671-9.

38. Aronson WJ, Glaspy JA, Reddy ST, Reese D, Heber D, Bagga D. Modulation of omega-3/omega-6 polyunsaturated ratios with dietary fish oils in men with prostate cancer. Urology. Aug 2001;58(2):283-8.

39. Bagga D, Wang L, Farias-Eisner R, Glaspy JA, Reddy ST. Differential effects of prostaglandin derived from omega-6 and omega-3 polyunsaturated fatty acids on COX-2 expression and IL-6 secretion. Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):1751-6.

40. Aggarwal BB, Shishodia S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol. 2006 May 14;71(10):1397-421.

41. Shishodia S, Majumdar S, Banerjee S, Aggarwal BB. Ursolic acid inhibits nuclear factor-kappaB activation induced by carcinogenic agents through suppression of IkappaBalpha kinase and p65 phosphorylation: correlation with down-regulation of cyclooxygenase 2, matrix metalloproteinase 9, and cyclin D1. Cancer Res. Aug 1 2003;63(15):4375-83.

42. Shishodia S, Sethi G, Konopleva M, Andreeff M, Aggarwal BB. A synthetic triterpenoid, CDDO-Me, inhibits IkappaBalpha kinase and enhances apoptosis induced by TNF and chemotherapeutic agents through down-regulation of expression of nuclear factor kappaB-regulated gene products in human leukemic cells. Clin Cancer Res. 2006 Mar 15;12(6):1828-38.

43. Tian Z, Lin G, Zheng RX, Huang F, Yang MS, Xiao PG. Anti-hepatoma activity and mechanism of ursolic acid and its derivatives isolated from Aralia decaisneana. World J Gastroenterol. 2006 Feb 14;12(6):874-9.

44. Attiga FA, Fernandez PM, Weeraratna AT, Manyak MJ, Patierno SR. Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases. Cancer Res. Aug 15 2000;60(16):4629-37.

45. Takada Y, Bhardwaj A, Potdar P, Aggarwal BB. Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-kappaB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation. Oncogene. Dec 9 2004;23(57):9247-58.

46. Brusselmans K, De Schrijver E, Heyns W, Verhoeven G, Swinnen JV. Epigallocatechin-3-gallate is a potent natural inhibitor of fatty acid synthase in intact cells and selectively induces apoptosis in prostate cancer cells. Int J Cancer. 2003 Oct 10;106(6):856-62.

47. Menendez JA, Colomer R, Lupu R. Inhibition of fatty acid synthase-dependent neoplastic lipogenesis as the mechanism of gamma-linolenic acid-induced toxicity to tumor cells: an extension to Nwankwo's hypothesis. Med Hypotheses. 2005;64(2):337-41.

48. Qiao S, Pennanen P, Nazarova N, Lou YR, Tuohimaa P. Inhibition of fatty acid synthase expression by 1alpha,25-dihydroxyvitamin D3 in prostate cancer cells. J Steroid Biochem Mol Biol. 2003 May;85(1):1-8.

49. Qiao S, Tuohimaa P. Vitamin D3 inhibits fatty acid synthase expression by stimulating the expression of long-chain fatty-acid-CoA ligase 3 in prostate cancer cells. FEBS Lett. 2004 Nov 19 2004;577(3):451-54.

50. Knowles LM, Axelrod F, Browne CD, Smith JW. A Fatty Acid Synthase Blockade Induces Tumor Cell-cycle Arrest by Down-regulating Skp2. J Biol Chem. 2004;279(29):30540-45.

51. Kridel SJ, Axelrod F, Rozenkrantz N, Smith JW. Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity. Cancer Res. 2004 Mar 15;64(6):2070-5.

52. Menendez JA, Vellon L, Lupu R. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene. Ann Oncol. 2005 Aug;16(8):1253-67.

53. Aalinkeel R, Bindukumar B, Reynolds JL, et al. The dietary bioflavonoid, quercetin, selectively induces apoptosis of prostate cancer cells by down-regulating the expression of heat shock protein 90. Prostate. 2008 Dec 1 2008;68(16):1773-89.

54. Narayanan NK, Narayanan BA, Bosland M, Condon MS, Nargi D. Docosahexaenoic acid in combination with celecoxib modulates HSP70 and p53 proteins in prostate cancer cells. Int J Cancer. 2006 Oct 1;119(7):1586-98.

55. Srirangam A, Mitra R, Wang M, et al. Effects of HIV protease inhibitor ritonavir on Akt-regulated cell proliferation in breast cancer. Clin Cancer Res. 2006 Mar 15;12(6):1883-96.

56. Neckers L. Heat shock protein 90 inhibition by 17-allylamino-17- demethoxygeldanamycin: a novel therapeutic approach for treating hormone-refractory prostate cancer. Clin Cancer Res. 2002 May;8(5):962-6.

57. Jiang C, Ganther H, Lu J. Monomethyl selenium--specific inhibition of MMP-2 and VEGF expression: implications for angiogenic switch regulation. Molecular carcinogenesis. Dec 2000;29(4):236-50.

58. Dorai T, Cao YC, Dorai B, Buttyan R, Katz AE. Therapeutic potential of curcumin in human prostate cancer. III. Curcumin inhibits proliferation, induces apoptosis, and inhibits angiogenesis of LNCaP prostate cancer cells in vivo. Prostate. Jun 1 2001;47(4):293-303.

59. Singh RP, Raina K, Sharma G, Agarwal R. Silibinin inhibits established prostate tumor growth, progression, invasion, and metastasis and suppresses tumor angiogenesis and epithelial-mesenchymal transition in transgenic adenocarcinoma of the mouse prostate model mice. Clin Cancer Res. 2008 Dec 1;14(23):7773-80.

60. Wu HT, Lin SH, Chen YH. Inhibition of cell proliferation and in vitro markers of angiogenesis by indole-3-carbinol, a major indole metabolite present in cruciferous vegetables. J Agric Food Chem. 2005 Jun 29;53(13):5164-9.

61. McLarty J, Bigelow RL, Smith M, Elmajian D, Ankem M, Cardelli JA. Tea polyphenols decrease serum levels of prostate-specific antigen, hepatocyte growth factor, and vascular endothelial growth factor in prostate cancer patients and inhibit production of hepatocyte growth factor and vascular endothelial growth factor in vitro. Cancer Prev Res (Phila). Jul 2009;2(7):673-82.

62. Aragon-Ching JB, Dahut WL. VEGF inhibitors and prostate cancer therapy. Curr Mol Pharmacol. 2009 Jun;2(2):161-8.

63. Lokeshwar BL, Selzer MG, Zhu BQ, Block NL, Golub LM. Inhibition of cell proliferation, invasion, tumor growth and metastasis by an oral non-antimicrobial tetracycline analog (COL-3) in a metastatic prostate cancer model. Int J Cancer. 2002 Mar 10;98(2):297-309.

64. Cheng L, Zhang S, Sweeney CJ, Kao C, Gardner TA, Eble JN. Androgen withdrawal inhibits tumor growth and is associated with decrease in angiogenesis and VEGF expression in androgen-independent CWR22Rv1 human prostate cancer model. Anticancer Res. Jul-Aug 2004;24(4):2135-40.

65. Nicholson B, Gulding K, Conaway M, Wedge SR, Theodorescu D. Combination antiangiogenic and androgen deprivation therapy for prostate cancer: a promising therapeutic approach. Clin Cancer Res. 2004 Dec 15;10(24):8728-34.

66. Fournier P, Boissier S, Filleur S, et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res. Nov 15 2002;62(22):6538-44.

67. Strum SB. A strategy of success in the treatment of prostate cancer. PCRI Insights. 2002;5(1):2-15.

68. Bemis DL, Capodice JL, Anastasiadis AG, Katz AE, Buttyan R. Zyflamend, a unique herbal preparation with nonselective COX inhibitory activity, induces apoptosis of prostate cancer cells that lack COX-2 expression. Nutr Cancer. 2005;52(2):202-12.

69. Nelson MA. Inhibition of lipoxygenase activity: implications for the treatment and chemoprevention of prostate cancer. Cancer Biol Ther. 2007 Feb;6(2):237.

70. Rafailov S, Cammack S, Stone BA, Katz AE. The role of Zyflamend, an herbal anti-inflammatory, as a potential chemopreventive agent against prostate cancer: a case report. Integr Cancer Ther. 2007 Mar;6(1):74-6.

71. Yan J, Xie B, Capodice JL, Katz AE. Zyflamend inhibits the expression and function of androgen receptor and acts synergistically with bicalutimide to inhibit prostate cancer cell growth. Prostate. Feb 2012;72(3):244-52.